Global Corticosteroids Market By Drug Class (Glucocorticoid, Mineralocorticoids) By Indication (Asthma, Inflammatory Bowel Diseases, Lupus, Rheumatoid arthritis, Chronic Obstructive Pulmonary Disease (COPD), Allergies, Multiple Sclerosis, Others) By Route of Administration (Oral, Nasal, Intravenous, Rectal, Others) By Forms (Tablets, Injectable Solution, Gel/ Creams, Sprays, Others) By End User (Hospitals, Specialty Clinics, Pharmacies (Online, Retail), Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Corticosteroids, which have anti-inflammatory characteristics, are used to treat or regulate a wide range of health issues. Reduced inflammation minimises tissue damage and pain, making it easier to manage the symptoms of diseases such as arthritis, asthma, and multiple sclerosis. The primary factors driving the growth of corticosteroids market are increased prevalence and number of patients, as well as the significant effect of corticosteroids for the stated indications. The COVID-19 pandemic has had a significant impact on global healthcare systems as well as the corticosteroids market. Clinical data suggested that patients with COPD and asthma had a lower rate of COVID-19 infection early in the pandemic, leading to the notion that inhaled corticosteroids could aid. A prospective meta-analysis of randomised trials for corticosteroid therapy for COVID-19 was also conducted by the World Health Organization in collaboration with investigators from seven corticosteroid trials. In terms of revenue, global corticosteroids market was valued at US$ 4.56 Bn in 2021 growing at a CAGR of 5.2% over the forecast period (2022 – 2030).
Drug Class Outlook
Based on the drug class segment, the global corticosteroids market is segmented into glucocorticoids and mineralocorticoids. Glucocorticoid are synthetic versions of steroid hormones produced naturally in the body. They serve a variety of purposes. One way to stop inflammation is to get into cells and decrease the proteins that cause inflammation. These glucocorticoids are used to treat various autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease. On the other hand, mineralocorticoids are used to keep electrolyte and water balance in the body and in particular, manage sodium and potassium retention in the kidneys caused due to various disorders. Thus, depending upon the intensity of inflammation above corticosteroid types are given to the patients.
Global Corticosteroids Market Revenue & Forecast, (US$ Million), 2015 – 2030
Indication Outlook
Based on the indication, the market is segmented into asthma, inflammatory bowel diseases, lupus, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), allergies, multiple sclerosis, others. In the last ten years, people suffering from allergies have been on the rise due to the drastically changing environmental conditions and the rising pollution. In 2022, it was recorded that 40% of kids and 30% of adults had allergies in the U.S. and urban contributed for 64%of asthma cases. Corticosteroids are widely being used to treat various allergies wherein it lowers the swelling and inflammation. Moreover, corticosteroids are available as nasal sprays, topical creams, pills and long-lasting injections. Additionally, the leading players in the market are investing into clinical trials for corticosteroids to treat various diseases which is anticipated to support the growth of global corticosteroids market in the upcoming years.
Route of Administration Outlook
Based on the route of administration, the market is segmented into oral, nasal, intravenous, rectal and others. The use of corticosteroids is mostly determined by the patient's disease and the doctor's subsequent decision. Two routes of administration are combined for specific conditions, such as orally and intra-articular injection for rheumatoid arthritis or alternated, such as orally and by inhalation for asthma. The route of administration for corticosteroid are chosen according to dosages required. For instance, when it comes to treating acute asthma attacks, oral corticosteroids are just as effective as intravenous medication. They come in tablet form that can be broken and blended with soft food or syrup, as well as liquid form in a variety of formulas. Lately with the advancements, leading players in the market are offering corticosteroids through creams and gels for skin disorders to reduce inflammation caused due to eczema, and psoriasis. Thus, with various forms and route of administration the demand for corticosteroids rose, which in turn is contributing to the growth of global corticosteroids market.
End User Outlook
Based on the end user segment, the global corticosteroids market is segmented into hospitals, specialty clinics, pharmacies and others. Hospitals have had the highest share in the global corticosteroids market in the year 2021. But on the other hand specialty clinics and online pharmacies are gaining huge popularity across the globe. People are opting for speciality physicians to treat various disorders and diseases. Moreover mild corticosteroids are being distributed through online pharmacies to treat mild allergies via over the counter, which has led to the rise in demand for corticosteroids in various countries. Thus with the rise in online pharmacies and speciality clinics the global corticosteroids market is anticipated to grow in the upcoming years.
Region Outlook
Based on the regions, North America had the highest share in the global corticosteroids market. Rheumatoid arthritis is a rising concern amongst a huge population in United States and Canada. According to Centers for Disease Control and Prevention in the United States, 1 in 4 adults had arthritis in 2020 and more than 1.36 million adults in the U.S. suffer from rheumatoid arthritis. Corticosteroids are primarily used to relieve the symptoms of acute pain and inflammation. Moreover, as corticosteroids are widely being used to treat various diseases in various forms such as tablets, inhalers and injectables the demand for them has grown considerably in the last few years. Furthermore, due to the presence of the leading players in the corticosteroids market, the supply of corticosteroids has been uniform which has been supporting the growth of corticosteroids market in North America.
Competitive Landscape
The report provides both, qualitative and quantitative research of global corticosteroids market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global corticosteroids market are listed below:
- Abbott
- AstraZeneca
- Cipla
- GlaxoSmithKline plc
- Merck & Co., Inc
- Novartis
- Pfizer
- Sanofi
- Other Industry Participants
Global Corticosteroid Market
By Drug Class
- Glucocorticoid
- Mineralocorticoids
By Indication
- Asthma
- Inflammatory bowel diseases
- Lupus
- Rheumatoid arthritis
- Chronic obstructive pulmonary disease (COPD)
- Allergies
- Multiple Sclerosis
- Others
By Route of administration
- Oral
- Nasal
- Intravenous
- Rectal
By Forms
- Tablets
- Injectable Solution
- Gel/ Creams
- Sprays
- Others
By End User
- Hospitals
- Specialty clinics
- Pharmacies
- Online
- Retail
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Corticosteroids Market
6. Market Synopsis:Â
Corticosteroids Market
7. Corticosteroids Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Corticosteroids Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Corticosteroids
Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Corticosteroids Market
8. Global Corticosteroids Market Analysis and Forecasts, 2022 –
2030
8.1. Overview
8.1.1. Global Corticosteroids Market Revenue (US$ Mn)
8.2. Global Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
8.2.1. Glucocorticoid
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 - 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. Mineralocorticoids
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Drug Class
9. Global Corticosteroids Market Analysis and Forecasts, 2022 –
2030
9.1. Overview
9.2. Global Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
9.2.1. Asthma
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Inflammatory bowel diseases
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Lupus
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Rheumatoid arthritis
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Chronic obstructive pulmonary disease (COPD)
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. Allergies
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.2.7. Multiple Sclerosis
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2021
9.2.7.5.1.2. Market
Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2021
9.2.7.5.2.2. Market
Forecast, 2022 - 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2021
9.2.7.5.3.2. Market
Forecast, 2022 - 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2021
9.2.7.5.4.2. Market
Forecast, 2022 - 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2021
9.2.7.5.5.2. Market
Forecast, 2022 - 2030
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 - 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market
Estimation, 2015 - 2021
9.2.8.5.1.2. Market
Forecast, 2022 - 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 - 2021
9.2.8.5.2.2. Market
Forecast, 2022 - 2030
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market
Estimation, 2015 - 2021
9.2.8.5.3.2. Market
Forecast, 2022 - 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 - 2021
9.2.8.5.4.2. Market
Forecast, 2022 - 2030
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market
Estimation, 2015 - 2021
9.2.8.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Indication
10. Global Corticosteroids Market Analysis and Forecasts, 2022 –
2030
10.1. Overview
10.2. Global Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Nasal
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Intravenous
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Rectal
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2021
10.2.5.3. Market Forecast, 2022 - 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market
Estimation, 2015 - 2021
10.2.5.5.1.2. Market
Forecast, 2022 - 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 - 2021
10.2.5.5.2.2. Market
Forecast, 2022 - 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market
Estimation, 2015 - 2021
10.2.5.5.3.2. Market
Forecast, 2022 - 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 - 2021
10.2.5.5.4.2. Market
Forecast, 2022 - 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market
Estimation, 2015 - 2021
10.2.5.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Route of administration
11. Global Corticosteroids Market Analysis and Forecasts, 2022 –
2030
11.1. Overview
11.2. Global Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
11.2.1. Tablets
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2021
11.2.1.3. Market Forecast, 2022 - 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2021
11.2.1.5.1.2. Market
Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2021
11.2.1.5.2.2. Market
Forecast, 2022 - 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2021
11.2.1.5.3.2. Market
Forecast, 2022 - 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2021
11.2.1.5.4.2. Market
Forecast, 2022 - 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2021
11.2.1.5.5.2. Market
Forecast, 2022 - 2030
11.2.2. Injectable Solutions
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2021
11.2.2.3. Market Forecast, 2022 - 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2021
11.2.2.5.1.2. Market
Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2021
11.2.2.5.2.2. Market
Forecast, 2022 - 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2021
11.2.2.5.3.2. Market
Forecast, 2022 - 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2021
11.2.2.5.4.2. Market
Forecast, 2022 - 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2021
11.2.2.5.5.2. Market
Forecast, 2022 - 2030
11.2.3. Gel/ Creams
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2021
11.2.3.3. Market Forecast, 2022 - 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2021
11.2.3.5.1.2. Market
Forecast, 2022 - 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2021
11.2.3.5.2.2. Market
Forecast, 2022 - 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2021
11.2.3.5.3.2. Market
Forecast, 2022 - 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2021
11.2.3.5.4.2. Market
Forecast, 2022 - 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2021
11.2.3.5.5.2. Market
Forecast, 2022 - 2030
11.2.4. Sprays
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 - 2021
11.2.4.3. Market Forecast, 2022 - 2030
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market
Estimation, 2015 - 2021
11.2.4.5.1.2. Market
Forecast, 2022 - 2030
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 - 2021
11.2.4.5.2.2. Market
Forecast, 2022 - 2030
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market
Estimation, 2015 - 2021
11.2.4.5.3.2. Market
Forecast, 2022 - 2030
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 - 2021
11.2.4.5.4.2. Market
Forecast, 2022 - 2030
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market
Estimation, 2015 - 2021
11.2.4.5.5.2. Market
Forecast, 2022 - 2030
11.2.5. Others
11.2.5.1. Definition
11.2.5.2. Market Estimation and Penetration, 2015 - 2021
11.2.5.3. Market Forecast, 2022 - 2030
11.2.5.4. Compound Annual Growth Rate (CAGR)
11.2.5.5. Regional Bifurcation
11.2.5.5.1. North America
11.2.5.5.1.1. Market
Estimation, 2015 - 2021
11.2.5.5.1.2. Market
Forecast, 2022 - 2030
11.2.5.5.2. Europe
11.2.5.5.2.1. Market
Estimation, 2015 - 2021
11.2.5.5.2.2. Market
Forecast, 2022 - 2030
11.2.5.5.3. Asia Pacific
11.2.5.5.3.1. Market
Estimation, 2015 - 2021
11.2.5.5.3.2. Market
Forecast, 2022 - 2030
11.2.5.5.4. Middle East and Africa
11.2.5.5.4.1. Market
Estimation, 2015 - 2021
11.2.5.5.4.2. Market
Forecast, 2022 - 2030
11.2.5.5.5. Latin America
11.2.5.5.5.1. Market
Estimation, 2015 - 2021
11.2.5.5.5.2. Market
Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Forms
12. Global Corticosteroids Market Analysis and Forecasts, 2022 –
2030
12.1. Overview
12.2. Global Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
12.2.1. Hospitals
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2015 - 2021
12.2.1.3. Market Forecast, 2022 - 2030
12.2.1.4. Compound Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market
Estimation, 2015 - 2021
12.2.1.5.1.2. Market
Forecast, 2022 - 2030
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 - 2021
12.2.1.5.2.2. Market
Forecast, 2022 - 2030
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market
Estimation, 2015 - 2021
12.2.1.5.3.2. Market
Forecast, 2022 - 2030
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 - 2021
12.2.1.5.4.2. Market
Forecast, 2022 - 2030
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market
Estimation, 2015 - 2021
12.2.1.5.5.2. Market
Forecast, 2022 - 2030
12.2.2. Specialty clinics
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2015 - 2021
12.2.2.3. Market Forecast, 2022 - 2030
12.2.2.4. Compound Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market
Estimation, 2015 - 2021
12.2.2.5.1.2. Market
Forecast, 2022 - 2030
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 - 2021
12.2.2.5.2.2. Market
Forecast, 2022 - 2030
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market
Estimation, 2015 - 2021
12.2.2.5.3.2. Market
Forecast, 2022 - 2030
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 - 2021
12.2.2.5.4.2. Market
Forecast, 2022 - 2030
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market
Estimation, 2015 - 2021
12.2.2.5.5.2. Market
Forecast, 2022 - 2030
12.2.3. Pharmacies (Definition, Market Estimation and Penetration, 2015
- 2021, Market Estimation (2015 - 2021), Market Forecast (2022 - 2030),
Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America,
Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on
Online , Retail)
12.2.3.1. Online
12.2.3.2. Retail
12.2.4. Others
12.2.4.1. Definition
12.2.4.2. Market Estimation and Penetration, 2015 - 2021
12.2.4.3. Market Forecast, 2022 - 2030
12.2.4.4. Compound Annual Growth Rate (CAGR)
12.2.4.5. Regional Bifurcation
12.2.4.5.1. North America
12.2.4.5.1.1. Market
Estimation, 2015 - 2021
12.2.4.5.1.2. Market
Forecast, 2022 - 2030
12.2.4.5.2. Europe
12.2.4.5.2.1. Market
Estimation, 2015 - 2021
12.2.4.5.2.2. Market
Forecast, 2022 - 2030
12.2.4.5.3. Asia Pacific
12.2.4.5.3.1. Market
Estimation, 2015 - 2021
12.2.4.5.3.2. Market
Forecast, 2022 - 2030
12.2.4.5.4. Middle East and Africa
12.2.4.5.4.1. Market
Estimation, 2015 - 2021
12.2.4.5.4.2. Market
Forecast, 2022 - 2030
12.2.4.5.5. Latin America
12.2.4.5.5.1. Market
Estimation, 2015 - 2021
12.2.4.5.5.2. Market
Forecast, 2022 - 2030
12.3. Key Segment for Channeling Investments
12.3.1. By End User
13. North America Corticosteroids Market Analysis and Forecasts, 2022
- 2030
13.1. Overview
13.1.1. North America Corticosteroids Market Revenue (US$ Mn)
13.2. North America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
13.2.1. Glucocorticoid
13.2.2. Mineralocorticoids
13.3. North America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
13.3.1. Asthma
13.3.2. Inflammatory bowel diseases
13.3.3. Lupus
13.3.4. Rheumatoid arthritis
13.3.5. Chronic obstructive pulmonary disease (COPD)
13.3.6. Allergies
13.3.7. Multiple Sclerosis
13.3.8. Others
13.4. North America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
13.4.1. Oral
13.4.2. Nasal
13.4.3. Intravenous
13.4.4. Rectal
13.4.5. Others
13.5. North America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
13.5.1. Tablets
13.5.2. Injectable Solutions
13.5.3. Gel/ Creams
13.5.4. Sprays
13.5.5. Others
13.6. North America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
13.6.1. Hospitals
13.6.2. Specialty clinics
13.6.3. Pharmacies
13.6.3.1. Online
13.6.3.2. Retail
13.6.4. Others
13.7. North America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Drug Class
13.7.1.1.1. Glucocorticoid
13.7.1.1.2. Mineralocorticoids
13.7.1.2. U.S Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Indication
13.7.1.2.1. Asthma
13.7.1.2.2. Inflammatory bowel diseases
13.7.1.2.3. Lupus
13.7.1.2.4. Rheumatoid arthritis
13.7.1.2.5. Chronic obstructive pulmonary disease (COPD)
13.7.1.2.6. Allergies
13.7.1.2.7. Multiple Sclerosis
13.7.1.2.8. Others
13.7.1.3. U.S Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Route of administration
13.7.1.3.1. Oral
13.7.1.3.2. Nasal
13.7.1.3.3. Intravenous
13.7.1.3.4. Rectal
13.7.1.3.5. Others
13.7.1.4. U.S Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Forms
13.7.1.4.1. Tablets
13.7.1.4.2. Injectable Solutions
13.7.1.4.3. Gel/ Creams
13.7.1.4.4. Sprays
13.7.1.4.5. Others
13.7.1.5. U.S Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
End User
13.7.1.5.1. Hospitals
13.7.1.5.2. Specialty clinics
13.7.1.5.3. Pharmacies
13.7.1.5.3.1. Online
13.7.1.5.3.2. Retail
13.7.1.5.4. Others
13.7.2. Canada
13.7.2.1. Canada Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
13.7.2.1.1. Glucocorticoid
13.7.2.1.2. Mineralocorticoids
13.7.2.2. Canada Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
13.7.2.2.1. Asthma
13.7.2.2.2. Inflammatory bowel diseases
13.7.2.2.3. Lupus
13.7.2.2.4. Rheumatoid arthritis
13.7.2.2.5. Chronic obstructive pulmonary disease (COPD)
13.7.2.2.6. Allergies
13.7.2.2.7. Multiple Sclerosis
13.7.2.2.8. Others
13.7.2.3. Canada Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
13.7.2.3.1. Oral
13.7.2.3.2. Nasal
13.7.2.3.3. Intravenous
13.7.2.3.4. Rectal
13.7.2.3.5. Others
13.7.2.4. Canada Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
13.7.2.4.1. Tablets
13.7.2.4.2. Injectable Solutions
13.7.2.4.3. Gel/ Creams
13.7.2.4.4. Sprays
13.7.2.4.5. Others
13.7.2.5. Canada Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
13.7.2.5.1. Hospitals
13.7.2.5.2. Specialty clinics
13.7.2.5.3. Pharmacies
13.7.2.5.3.1. Online
13.7.2.5.3.2. Retail
13.7.2.5.4. Others
13.7.3. Mexico
13.7.3.1. Mexico Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
13.7.3.1.1. Glucocorticoid
13.7.3.1.2. Mineralocorticoids
13.7.3.2. Mexico Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
13.7.3.2.1. Asthma
13.7.3.2.2. Inflammatory bowel diseases
13.7.3.2.3. Lupus
13.7.3.2.4. Rheumatoid arthritis
13.7.3.2.5. Chronic obstructive pulmonary disease (COPD)
13.7.3.2.6. Allergies
13.7.3.2.7. Multiple Sclerosis
13.7.3.2.8. Others
13.7.3.3. Mexico Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
13.7.3.3.1. Oral
13.7.3.3.2. Nasal
13.7.3.3.3. Intravenous
13.7.3.3.4. Rectal
13.7.3.3.5. Others
13.7.3.4. Mexico Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
13.7.3.4.1. Tablets
13.7.3.4.2. Injectable Solutions
13.7.3.4.3. Gel/ Creams
13.7.3.4.4. Sprays
13.7.3.4.5. Others
13.7.3.5. Mexico Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
13.7.3.5.1. Hospitals
13.7.3.5.2. Specialty clinics
13.7.3.5.3. Pharmacies
13.7.3.5.3.1. Online
13.7.3.5.3.2. Retail
13.7.3.5.4. Others
13.7.4. Rest of North America
13.7.4.1. Rest of North America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Drug Class
13.7.4.1.1. Glucocorticoid
13.7.4.1.2. Mineralocorticoids
13.7.4.2. Rest of North America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.4.2.1. Asthma
13.7.4.2.2. Inflammatory bowel diseases
13.7.4.2.3. Lupus
13.7.4.2.4. Rheumatoid arthritis
13.7.4.2.5. Chronic obstructive pulmonary disease (COPD)
13.7.4.2.6. Allergies
13.7.4.2.7. Multiple Sclerosis
13.7.4.2.8. Others
13.7.4.3. Rest of North America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Route of administration
13.7.4.3.1. Oral
13.7.4.3.2. Nasal
13.7.4.3.3. Intravenous
13.7.4.3.4. Rectal
13.7.4.3.5. Others
13.7.4.4. Rest of North America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Forms
13.7.4.4.1. Tablets
13.7.4.4.2. Injectable Solutions
13.7.4.4.3. Gel/ Creams
13.7.4.4.4. Sprays
13.7.4.4.5. Others
13.7.4.5. Rest of North America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By End User
13.7.4.5.1. Hospitals
13.7.4.5.2. Specialty clinics
13.7.4.5.3. Pharmacies
13.7.4.5.3.1. Online
13.7.4.5.3.2. Retail
13.7.4.5.4. Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Drug Class
13.8.3. By Indication
13.8.4. By Route of administration
13.8.5. By Forms
13.8.6. By End User
14. Europe Corticosteroids Market Analysis and Forecasts, 2022 -
2030
14.1. Overview
14.1.1. Europe Corticosteroids Market Revenue (US$ Mn)
14.2. Europe Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.2.1. Glucocorticoid
14.2.2. Mineralocorticoids
14.3. Europe Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
14.3.1. Asthma
14.3.2. Inflammatory bowel diseases
14.3.3. Lupus
14.3.4. Rheumatoid arthritis
14.3.5. Chronic obstructive pulmonary disease (COPD)
14.3.6. Allergies
14.3.7. Multiple Sclerosis
14.3.8. Others
14.4. Europe Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
14.4.1. Oral
14.4.2. Nasal
14.4.3. Intravenous
14.4.4. Rectal
14.4.5. Others
14.5. Europe Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
14.5.1. Tablets
14.5.2. Injectable Solutions
14.5.3. Gel/ Creams
14.5.4. Sprays
14.5.5. Others
14.6. Europe Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
14.6.1. Hospitals
14.6.2. Specialty clinics
14.6.3. Pharmacies
14.6.3.1. Online
14.6.3.2. Retail
14.6.4. Others
14.7. Europe Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Country
14.7.1. France
14.7.1.1. France Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.7.1.1.1. Glucocorticoid
14.7.1.1.2. Mineralocorticoids
14.7.1.2. France Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
14.7.1.2.1. Asthma
14.7.1.2.2. Inflammatory bowel diseases
14.7.1.2.3. Lupus
14.7.1.2.4. Rheumatoid arthritis
14.7.1.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.1.2.6. Allergies
14.7.1.2.7. Multiple Sclerosis
14.7.1.2.8. Others
14.7.1.3. France Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
14.7.1.3.1. Oral
14.7.1.3.2. Nasal
14.7.1.3.3. Intravenous
14.7.1.3.4. Rectal
14.7.1.3.5. Others
14.7.1.4. France Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
14.7.1.4.1. Tablets
14.7.1.4.2. Injectable Solutions
14.7.1.4.3. Gel/ Creams
14.7.1.4.4. Sprays
14.7.1.4.5. Others
14.7.1.5. France Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
14.7.1.5.1. Hospitals
14.7.1.5.2. Specialty clinics
14.7.1.5.3. Pharmacies
14.7.1.5.3.1. Online
14.7.1.5.3.2. Retail
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1. The UK Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.7.2.1.1. Glucocorticoid
14.7.2.1.2. Mineralocorticoids
14.7.2.2. The UK Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
14.7.2.2.1. Asthma
14.7.2.2.2. Inflammatory bowel diseases
14.7.2.2.3. Lupus
14.7.2.2.4. Rheumatoid arthritis
14.7.2.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.2.2.6. Allergies
14.7.2.2.7. Multiple Sclerosis
14.7.2.2.8. Others
14.7.2.3. The UK Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
14.7.2.3.1. Oral
14.7.2.3.2. Nasal
14.7.2.3.3. Intravenous
14.7.2.3.4. Rectal
14.7.2.3.5. Others
14.7.2.4. The UK Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
14.7.2.4.1. Tablets
14.7.2.4.2. Injectable Solutions
14.7.2.4.3. Gel/ Creams
14.7.2.4.4. Sprays
14.7.2.4.5. Others
14.7.2.5. The UK Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
14.7.2.5.1. Hospitals
14.7.2.5.2. Specialty clinics
14.7.2.5.3. Pharmacies
14.7.2.5.3.1. Online
14.7.2.5.3.2. Retail
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1. Spain Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.7.3.1.1. Glucocorticoid
14.7.3.1.2. Mineralocorticoids
14.7.3.2. Spain Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
14.7.3.2.1. Asthma
14.7.3.2.2. Inflammatory bowel diseases
14.7.3.2.3. Lupus
14.7.3.2.4. Rheumatoid arthritis
14.7.3.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.3.2.6. Allergies
14.7.3.2.7. Multiple Sclerosis
14.7.3.2.8. Others
14.7.3.3. Spain Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
14.7.3.3.1. Oral
14.7.3.3.2. Nasal
14.7.3.3.3. Intravenous
14.7.3.3.4. Rectal
14.7.3.3.5. Others
14.7.3.4. Spain Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
14.7.3.4.1. Tablets
14.7.3.4.2. Injectable Solutions
14.7.3.4.3. Gel/ Creams
14.7.3.4.4. Sprays
14.7.3.4.5. Others
14.7.3.5. Spain Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
14.7.3.5.1. Hospitals
14.7.3.5.2. Specialty clinics
14.7.3.5.3. Pharmacies
14.7.3.5.3.1. Online
14.7.3.5.3.2. Retail
14.7.3.5.4. Others
14.7.4. Germany
14.7.4.1. Germany Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.7.4.1.1. Glucocorticoid
14.7.4.1.2. Mineralocorticoids
14.7.4.2. Germany Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
14.7.4.2.1. Asthma
14.7.4.2.2. Inflammatory bowel diseases
14.7.4.2.3. Lupus
14.7.4.2.4. Rheumatoid arthritis
14.7.4.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.4.2.6. Allergies
14.7.4.2.7. Multiple Sclerosis
14.7.4.2.8. Others
14.7.4.3. Germany Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
14.7.4.3.1. Oral
14.7.4.3.2. Nasal
14.7.4.3.3. Intravenous
14.7.4.3.4. Rectal
14.7.4.3.5. Others
14.7.4.4. Germany Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
14.7.4.4.1. Tablets
14.7.4.4.2. Injectable Solutions
14.7.4.4.3. Gel/ Creams
14.7.4.4.4. Sprays
14.7.4.4.5. Others
14.7.4.5. Germany Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
14.7.4.5.1. Hospitals
14.7.4.5.2. Specialty clinics
14.7.4.5.3. Pharmacies
14.7.4.5.3.1. Online
14.7.4.5.3.2. Retail
14.7.4.5.4. Others
14.7.5. Italy
14.7.5.1. Italy Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
14.7.5.1.1. Glucocorticoid
14.7.5.1.2. Mineralocorticoids
14.7.5.2. Italy Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
14.7.5.2.1. Asthma
14.7.5.2.2. Inflammatory bowel diseases
14.7.5.2.3. Lupus
14.7.5.2.4. Rheumatoid arthritis
14.7.5.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.5.2.6. Allergies
14.7.5.2.7. Multiple Sclerosis
14.7.5.2.8. Others
14.7.5.3. Italy Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
14.7.5.3.1. Oral
14.7.5.3.2. Nasal
14.7.5.3.3. Intravenous
14.7.5.3.4. Rectal
14.7.5.3.5. Others
14.7.5.4. Italy Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
14.7.5.4.1. Tablets
14.7.5.4.2. Injectable Solutions
14.7.5.4.3. Gel/ Creams
14.7.5.4.4. Sprays
14.7.5.4.5. Others
14.7.5.5. Italy Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
14.7.5.5.1. Hospitals
14.7.5.5.2. Specialty clinics
14.7.5.5.3. Pharmacies
14.7.5.5.3.1. Online
14.7.5.5.3.2. Retail
14.7.5.5.4. Others
14.7.6. Nordic Countries
14.7.6.1. Nordic Countries Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.7.6.1.1. Glucocorticoid
14.7.6.1.2. Mineralocorticoids
14.7.6.2. Nordic Countries Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
14.7.6.2.1. Asthma
14.7.6.2.2. Inflammatory bowel diseases
14.7.6.2.3. Lupus
14.7.6.2.4. Rheumatoid arthritis
14.7.6.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.6.2.6. Allergies
14.7.6.2.7. Multiple Sclerosis
14.7.6.2.8. Others
14.7.6.3. Nordic Countries Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
14.7.6.3.1. Oral
14.7.6.3.2. Nasal
14.7.6.3.3. Intravenous
14.7.6.3.4. Rectal
14.7.6.3.5. Others
14.7.6.4. Nordic Countries Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
14.7.6.4.1. Tablets
14.7.6.4.2. Injectable Solutions
14.7.6.4.3. Gel/ Creams
14.7.6.4.4. Sprays
14.7.6.4.5. Others
14.7.6.5. Nordic Countries Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
14.7.6.5.1. Hospitals
14.7.6.5.2. Specialty clinics
14.7.6.5.3. Pharmacies
14.7.6.5.3.1. Online
14.7.6.5.3.2. Retail
14.7.6.5.4. Others
14.7.6.6. Nordic Countries Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux Union
14.7.7.1. Benelux Union Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.7.7.1.1. Glucocorticoid
14.7.7.1.2. Mineralocorticoids
14.7.7.2. Benelux Union Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
14.7.7.2.1. Asthma
14.7.7.2.2. Inflammatory bowel diseases
14.7.7.2.3. Lupus
14.7.7.2.4. Rheumatoid arthritis
14.7.7.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.7.2.6. Allergies
14.7.7.2.7. Multiple Sclerosis
14.7.7.2.8. Others
14.7.7.3. Benelux Union Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
14.7.7.3.1. Oral
14.7.7.3.2. Nasal
14.7.7.3.3. Intravenous
14.7.7.3.4. Rectal
14.7.7.3.5. Others
14.7.7.4. Benelux Union Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
14.7.7.4.1. Tablets
14.7.7.4.2. Injectable Solutions
14.7.7.4.3. Gel/ Creams
14.7.7.4.4. Sprays
14.7.7.4.5. Others
14.7.7.5. Benelux Union Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
14.7.7.5.1. Hospitals
14.7.7.5.2. Specialty clinics
14.7.7.5.3. Pharmacies
14.7.7.5.3.1. Online
14.7.7.5.3.2. Retail
14.7.7.5.4. Others
14.7.7.6. Benelux Union Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of Europe
14.7.8.1. Rest of Europe Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.7.8.1.1. Glucocorticoid
14.7.8.1.2. Mineralocorticoids
14.7.8.2. Rest of Europe Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
14.7.8.2.1. Asthma
14.7.8.2.2. Inflammatory bowel diseases
14.7.8.2.3. Lupus
14.7.8.2.4. Rheumatoid arthritis
14.7.8.2.5. Chronic obstructive pulmonary disease (COPD)
14.7.8.2.6. Allergies
14.7.8.2.7. Multiple Sclerosis
14.7.8.2.8. Others
14.7.8.3. Rest of Europe Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
14.7.8.3.1. Oral
14.7.8.3.2. Nasal
14.7.8.3.3. Intravenous
14.7.8.3.4. Rectal
14.7.8.3.5. Others
14.7.8.4. Rest of Europe Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
14.7.8.4.1. Tablets
14.7.8.4.2. Injectable Solutions
14.7.8.4.3. Gel/ Creams
14.7.8.4.4. Sprays
14.7.8.4.5. Others
14.7.8.5. Rest of Europe Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
14.7.8.5.1. Hospitals
14.7.8.5.2. Specialty clinics
14.7.8.5.3. Pharmacies
14.7.8.5.3.1. Online
14.7.8.5.3.2. Retail
14.7.8.5.4. Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Drug Class
14.8.3. By Indication
14.8.4. By Route of administration
14.8.5. By Forms
14.8.6. By End User
15. Asia Pacific Corticosteroids Market Analysis and Forecasts, 2022
- 2030
15.1. Overview
15.1.1. Asia Pacific Corticosteroids Market Revenue (US$ Mn)
15.2. Asia Pacific Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.2.1. Glucocorticoid
15.2.2. Mineralocorticoids
15.3. Asia Pacific Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
15.3.1. Asthma
15.3.2. Inflammatory bowel diseases
15.3.3. Lupus
15.3.4. Rheumatoid arthritis
15.3.5. Chronic obstructive pulmonary disease (COPD)
15.3.6. Allergies
15.3.7. Multiple Sclerosis
15.3.8. Others
15.4. Asia Pacific Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
15.4.1. Oral
15.4.2. Nasal
15.4.3. Intravenous
15.4.4. Rectal
15.4.5. Others
15.5. Asia Pacific Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
15.5.1. Tablets
15.5.2. Injectable Solutions
15.5.3. Gel/ Creams
15.5.4. Sprays
15.5.5. Others
15.6. Asia Pacific Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
15.6.1. Hospitals
15.6.2. Specialty clinics
15.6.3. Pharmacies
15.6.3.1. Online
15.6.3.2. Retail
15.6.4. Others
15.7. Asia Pacific Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Country
15.7.1. China
15.7.1.1. China Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
15.7.1.1.1. Glucocorticoid
15.7.1.1.2. Mineralocorticoids
15.7.1.2. China Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
15.7.1.2.1. Asthma
15.7.1.2.2. Inflammatory bowel diseases
15.7.1.2.3. Lupus
15.7.1.2.4. Rheumatoid arthritis
15.7.1.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.1.2.6. Allergies
15.7.1.2.7. Multiple Sclerosis
15.7.1.2.8. Others
15.7.1.3. China Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
15.7.1.3.1. Oral
15.7.1.3.2. Nasal
15.7.1.3.3. Intravenous
15.7.1.3.4. Rectal
15.7.1.3.5. Others
15.7.1.4. China Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
15.7.1.4.1. Tablets
15.7.1.4.2. Injectable Solutions
15.7.1.4.3. Gel/ Creams
15.7.1.4.4. Sprays
15.7.1.4.5. Others
15.7.1.5. China Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
15.7.1.5.1. Hospitals
15.7.1.5.2. Specialty clinics
15.7.1.5.3. Pharmacies
15.7.1.5.3.1. Online
15.7.1.5.3.2. Retail
15.7.1.5.4. Others
15.7.2. Japan
15.7.2.1. Japan Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
15.7.2.1.1. Glucocorticoid
15.7.2.1.2. Mineralocorticoids
15.7.2.2. Japan Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
15.7.2.2.1. Asthma
15.7.2.2.2. Inflammatory bowel diseases
15.7.2.2.3. Lupus
15.7.2.2.4. Rheumatoid arthritis
15.7.2.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.2.2.6. Allergies
15.7.2.2.7. Multiple Sclerosis
15.7.2.2.8. Others
15.7.2.3. Japan Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
15.7.2.3.1. Oral
15.7.2.3.2. Nasal
15.7.2.3.3. Intravenous
15.7.2.3.4. Rectal
15.7.2.3.5. Others
15.7.2.4. Japan Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
15.7.2.4.1. Tablets
15.7.2.4.2. Injectable Solutions
15.7.2.4.3. Gel/ Creams
15.7.2.4.4. Sprays
15.7.2.4.5. Others
15.7.2.5. Japan Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
15.7.2.5.1. Hospitals
15.7.2.5.2. Specialty clinics
15.7.2.5.3. Pharmacies
15.7.2.5.3.1. Online
15.7.2.5.3.2. Retail
15.7.2.5.4. Others
15.7.3. India
15.7.3.1. India Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
15.7.3.1.1. Glucocorticoid
15.7.3.1.2. Mineralocorticoids
15.7.3.2. India Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
15.7.3.2.1. Asthma
15.7.3.2.2. Inflammatory bowel diseases
15.7.3.2.3. Lupus
15.7.3.2.4. Rheumatoid arthritis
15.7.3.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.3.2.6. Allergies
15.7.3.2.7. Multiple Sclerosis
15.7.3.2.8. Others
15.7.3.3. India Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
15.7.3.3.1. Oral
15.7.3.3.2. Nasal
15.7.3.3.3. Intravenous
15.7.3.3.4. Rectal
15.7.3.3.5. Others
15.7.3.4. India Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
15.7.3.4.1. Tablets
15.7.3.4.2. Injectable Solutions
15.7.3.4.3. Gel/ Creams
15.7.3.4.4. Sprays
15.7.3.4.5. Others
15.7.3.5. India Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
15.7.3.5.1. Hospitals
15.7.3.5.2. Specialty clinics
15.7.3.5.3. Pharmacies
15.7.3.5.3.1. Online
15.7.3.5.3.2. Retail
15.7.3.5.4. Others
15.7.4. New Zealand
15.7.4.1. New Zealand Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.4.1.1. Glucocorticoid
15.7.4.1.2. Mineralocorticoids
15.7.4.2. New Zealand Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
15.7.4.2.1. Asthma
15.7.4.2.2. Inflammatory bowel diseases
15.7.4.2.3. Lupus
15.7.4.2.4. Rheumatoid arthritis
15.7.4.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.4.2.6. Allergies
15.7.4.2.7. Multiple Sclerosis
15.7.4.2.8. Others
15.7.4.3. New Zealand Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
15.7.4.3.1. Oral
15.7.4.3.2. Nasal
15.7.4.3.3. Intravenous
15.7.4.3.4. Rectal
15.7.4.3.5. Others
15.7.4.4. New Zealand Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
15.7.4.4.1. Tablets
15.7.4.4.2. Injectable Solutions
15.7.4.4.3. Gel/ Creams
15.7.4.4.4. Sprays
15.7.4.4.5. Others
15.7.4.5. New Zealand Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
15.7.4.5.1. Hospitals
15.7.4.5.2. Specialty clinics
15.7.4.5.3. Pharmacies
15.7.4.5.3.1. Online
15.7.4.5.3.2. Retail
15.7.4.5.4. Others
15.7.5. Australia
15.7.5.1. Australia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.5.1.1. Glucocorticoid
15.7.5.1.2. Mineralocorticoids
15.7.5.2. Australia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
15.7.5.2.1. Asthma
15.7.5.2.2. Inflammatory bowel diseases
15.7.5.2.3. Lupus
15.7.5.2.4. Rheumatoid arthritis
15.7.5.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.5.2.6. Allergies
15.7.5.2.7. Multiple Sclerosis
15.7.5.2.8. Others
15.7.5.3. Australia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
15.7.5.3.1. Oral
15.7.5.3.2. Nasal
15.7.5.3.3. Intravenous
15.7.5.3.4. Rectal
15.7.5.3.5. Others
15.7.5.4. Australia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
15.7.5.4.1. Tablets
15.7.5.4.2. Injectable Solutions
15.7.5.4.3. Gel/ Creams
15.7.5.4.4. Sprays
15.7.5.4.5. Others
15.7.5.5. Australia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
15.7.5.5.1. Hospitals
15.7.5.5.2. Specialty clinics
15.7.5.5.3. Pharmacies
15.7.5.5.3.1. Online
15.7.5.5.3.2. Retail
15.7.5.5.4. Others
15.7.6. South Korea
15.7.6.1. South Korea Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.6.1.1. Glucocorticoid
15.7.6.1.2. Mineralocorticoids
15.7.6.2. South Korea Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
15.7.6.2.1. Asthma
15.7.6.2.2. Inflammatory bowel diseases
15.7.6.2.3. Lupus
15.7.6.2.4. Rheumatoid arthritis
15.7.6.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.6.2.6. Allergies
15.7.6.2.7. Multiple Sclerosis
15.7.6.2.8. Others
15.7.6.3. South Korea Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
15.7.6.3.1. Oral
15.7.6.3.2. Nasal
15.7.6.3.3. Intravenous
15.7.6.3.4. Rectal
15.7.6.3.5. Others
15.7.6.4. South Korea Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
15.7.6.4.1. Tablets
15.7.6.4.2. Injectable Solutions
15.7.6.4.3. Gel/ Creams
15.7.6.4.4. Sprays
15.7.6.4.5. Others
15.7.6.5. South Korea Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
15.7.6.5.1. Hospitals
15.7.6.5.2. Specialty clinics
15.7.6.5.3. Pharmacies
15.7.6.5.3.1. Online
15.7.6.5.3.2. Retail
15.7.6.5.4. Others
15.7.7. Southeast Asia
15.7.7.1. Southeast Asia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
15.7.7.1.1. Glucocorticoid
15.7.7.1.2. Mineralocorticoids
15.7.7.2. Southeast Asia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
15.7.7.2.1. Asthma
15.7.7.2.2. Inflammatory bowel diseases
15.7.7.2.3. Lupus
15.7.7.2.4. Rheumatoid arthritis
15.7.7.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.7.2.6. Allergies
15.7.7.2.7. Multiple Sclerosis
15.7.7.2.8. Others
15.7.7.3. Southeast Asia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
15.7.7.3.1. Oral
15.7.7.3.2. Nasal
15.7.7.3.3. Intravenous
15.7.7.3.4. Rectal
15.7.7.3.5. Others
15.7.7.4. Southeast Asia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
15.7.7.4.1. Tablets
15.7.7.4.2. Injectable Solutions
15.7.7.4.3. Gel/ Creams
15.7.7.4.4. Sprays
15.7.7.4.5. Others
15.7.7.5. Southeast Asia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
15.7.7.5.1. Hospitals
15.7.7.5.2. Specialty clinics
15.7.7.5.3. Pharmacies
15.7.7.5.3.1. Online
15.7.7.5.3.2. Retail
15.7.7.5.4. Others
15.7.7.6. Southeast Asia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1. Rest of Asia Pacific Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Drug Class
15.7.8.1.1. Glucocorticoid
15.7.8.1.2. Mineralocorticoids
15.7.8.2. Rest of Asia Pacific Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.8.2.1. Asthma
15.7.8.2.2. Inflammatory bowel diseases
15.7.8.2.3. Lupus
15.7.8.2.4. Rheumatoid arthritis
15.7.8.2.5. Chronic obstructive pulmonary disease (COPD)
15.7.8.2.6. Allergies
15.7.8.2.7. Multiple Sclerosis
15.7.8.2.8. Others
15.7.8.3. Rest of Asia Pacific Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Route of administration
15.7.8.3.1. Oral
15.7.8.3.2. Nasal
15.7.8.3.3. Intravenous
15.7.8.3.4. Rectal
15.7.8.3.5. Others
15.7.8.4. Rest of Asia Pacific Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Forms
15.7.8.4.1. Tablets
15.7.8.4.2. Injectable Solutions
15.7.8.4.3. Gel/ Creams
15.7.8.4.4. Sprays
15.7.8.4.5. Others
15.7.8.5. Rest of Asia Pacific Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By End User
15.7.8.5.1. Hospitals
15.7.8.5.2. Specialty clinics
15.7.8.5.3. Pharmacies
15.7.8.5.3.1. Online
15.7.8.5.3.2. Retail
15.7.8.5.4. Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Drug Class
15.8.3. By Indication
15.8.4. By Route of administration
15.8.5. By Forms
15.8.6. By End User
16. Middle East and Africa Corticosteroids Market Analysis and
Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
16.2. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Drug Class
16.2.1. Glucocorticoid
16.2.2. Mineralocorticoids
16.3. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Indication
16.3.1. Asthma
16.3.2. Inflammatory bowel diseases
16.3.3. Lupus
16.3.4. Rheumatoid arthritis
16.3.5. Chronic obstructive pulmonary disease (COPD)
16.3.6. Allergies
16.3.7. Multiple Sclerosis
16.3.8. Others
16.4. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Route of administration
16.4.1. Oral
16.4.2. Nasal
16.4.3. Intravenous
16.4.4. Rectal
16.4.5. Others
16.5. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Forms
16.5.1. Tablets
16.5.2. Injectable Solutions
16.5.3. Gel/ Creams
16.5.4. Sprays
16.5.5. Others
16.6. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By End User
16.6.1. Hospitals
16.6.2. Specialty clinics
16.6.3. Pharmacies
16.6.3.1. Online
16.6.3.2. Retail
16.6.4. Others
16.7. Middle East and Africa Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1. Saudi Arabia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.7.1.1.1. Glucocorticoid
16.7.1.1.2. Mineralocorticoids
16.7.1.2. Saudi Arabia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
16.7.1.2.1. Asthma
16.7.1.2.2. Inflammatory bowel diseases
16.7.1.2.3. Lupus
16.7.1.2.4. Rheumatoid arthritis
16.7.1.2.5. Chronic obstructive pulmonary disease (COPD)
16.7.1.2.6. Allergies
16.7.1.2.7. Multiple Sclerosis
16.7.1.2.8. Others
16.7.1.3. Saudi Arabia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
16.7.1.3.1. Oral
16.7.1.3.2. Nasal
16.7.1.3.3. Intravenous
16.7.1.3.4. Rectal
16.7.1.3.5. Others
16.7.1.4. Saudi Arabia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
16.7.1.4.1. Tablets
16.7.1.4.2. Injectable Solutions
16.7.1.4.3. Gel/ Creams
16.7.1.4.4. Sprays
16.7.1.4.5. Others
16.7.1.5. Saudi Arabia Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.1.5.1. Hospitals
16.7.1.5.2. Specialty clinics
16.7.1.5.3. Pharmacies
16.7.1.5.3.1. Online
16.7.1.5.3.2. Retail
16.7.1.5.4. Others
16.7.2. UAE
16.7.2.1. UAE Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Drug Class
16.7.2.1.1. Glucocorticoid
16.7.2.1.2. Mineralocorticoids
16.7.2.2. UAE Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Indication
16.7.2.2.1. Asthma
16.7.2.2.2. Inflammatory bowel diseases
16.7.2.2.3. Lupus
16.7.2.2.4. Rheumatoid arthritis
16.7.2.2.5. Chronic obstructive pulmonary disease (COPD)
16.7.2.2.6. Allergies
16.7.2.2.7. Multiple Sclerosis
16.7.2.2.8. Others
16.7.2.3. UAE Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Route of administration
16.7.2.3.1. Oral
16.7.2.3.2. Nasal
16.7.2.3.3. Intravenous
16.7.2.3.4. Rectal
16.7.2.3.5. Others
16.7.2.4. UAE Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
Forms
16.7.2.4.1. Tablets
16.7.2.4.2. Injectable Solutions
16.7.2.4.3. Gel/ Creams
16.7.2.4.4. Sprays
16.7.2.4.5. Others
16.7.2.5. UAE Corticosteroids Market Revenue (US$ Mn) and Forecasts, By
End User
16.7.2.5.1. Hospitals
16.7.2.5.2. Specialty clinics
16.7.2.5.3. Pharmacies
16.7.2.5.3.1. Online
16.7.2.5.3.2. Retail
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1. Egypt Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
16.7.3.1.1. Glucocorticoid
16.7.3.1.2. Mineralocorticoids
16.7.3.2. Egypt Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
16.7.3.2.1. Asthma
16.7.3.2.2. Inflammatory bowel diseases
16.7.3.2.3. Lupus
16.7.3.2.4. Rheumatoid arthritis
16.7.3.2.5. Chronic obstructive pulmonary disease (COPD)
16.7.3.2.6. Allergies
16.7.3.2.7. Multiple Sclerosis
16.7.3.2.8. Others
16.7.3.3. Egypt Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
16.7.3.3.1. Oral
16.7.3.3.2. Nasal
16.7.3.3.3. Intravenous
16.7.3.3.4. Rectal
16.7.3.3.5. Others
16.7.3.4. Egypt Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
16.7.3.4.1. Tablets
16.7.3.4.2. Injectable Solutions
16.7.3.4.3. Gel/ Creams
16.7.3.4.4. Sprays
16.7.3.4.5. Others
16.7.3.5. Egypt Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
16.7.3.5.1. Hospitals
16.7.3.5.2. Specialty clinics
16.7.3.5.3. Pharmacies
16.7.3.5.3.1. Online
16.7.3.5.3.2. Retail
16.7.3.5.4. Others
16.7.4. Kuwait
16.7.4.1. Kuwait Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
16.7.4.1.1. Glucocorticoid
16.7.4.1.2. Mineralocorticoids
16.7.4.2. Kuwait Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
16.7.4.2.1. Asthma
16.7.4.2.2. Inflammatory bowel diseases
16.7.4.2.3. Lupus
16.7.4.2.4. Rheumatoid arthritis
16.7.4.2.5. Chronic obstructive pulmonary disease (COPD)
16.7.4.2.6. Allergies
16.7.4.2.7. Multiple Sclerosis
16.7.4.2.8. Others
16.7.4.3. Kuwait Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
16.7.4.3.1. Oral
16.7.4.3.2. Nasal
16.7.4.3.3. Intravenous
16.7.4.3.4. Rectal
16.7.4.3.5. Others
16.7.4.4. Kuwait Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
16.7.4.4.1. Tablets
16.7.4.4.2. Injectable Solutions
16.7.4.4.3. Gel/ Creams
16.7.4.4.4. Sprays
16.7.4.4.5. Others
16.7.4.5. Kuwait Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
16.7.4.5.1. Hospitals
16.7.4.5.2. Specialty clinics
16.7.4.5.3. Pharmacies
16.7.4.5.3.1. Online
16.7.4.5.3.2. Retail
16.7.4.5.4. Others
16.7.5. South Africa
16.7.5.1. South Africa Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.7.5.1.1. Glucocorticoid
16.7.5.1.2. Mineralocorticoids
16.7.5.2. South Africa Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
16.7.5.2.1. Asthma
16.7.5.2.2. Inflammatory bowel diseases
16.7.5.2.3. Lupus
16.7.5.2.4. Rheumatoid arthritis
16.7.5.2.5. Chronic obstructive pulmonary disease (COPD)
16.7.5.2.6. Allergies
16.7.5.2.7. Multiple Sclerosis
16.7.5.2.8. Others
16.7.5.3. South Africa Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
16.7.5.3.1. Oral
16.7.5.3.2. Nasal
16.7.5.3.3. Intravenous
16.7.5.3.4. Rectal
16.7.5.3.5. Others
16.7.5.4. South Africa Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
16.7.5.4.1. Tablets
16.7.5.4.2. Injectable Solutions
16.7.5.4.3. Gel/ Creams
16.7.5.4.4. Sprays
16.7.5.4.5. Others
16.7.5.5. South Africa Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.5.5.1. Hospitals
16.7.5.5.2. Specialty clinics
16.7.5.5.3. Pharmacies
16.7.5.5.3.1. Online
16.7.5.5.3.2. Retail
16.7.5.5.4. Others
16.7.6. Rest of Middle East & Africa
16.7.6.1. Rest of Middle East & Africa Corticosteroids Market
Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.6.1.1. Glucocorticoid
16.7.6.1.2. Mineralocorticoids
16.7.6.2. Rest of Middle East & Africa Corticosteroids Market
Revenue (US$ Mn) and Forecasts, By Indication
16.7.6.2.1. Asthma
16.7.6.2.2. Inflammatory bowel diseases
16.7.6.2.3. Lupus
16.7.6.2.4. Rheumatoid arthritis
16.7.6.2.5. Chronic obstructive pulmonary disease (COPD)
16.7.6.2.6. Allergies
16.7.6.2.7. Multiple Sclerosis
16.7.6.2.8. Others
16.7.6.3. Rest of Middle East & Africa Corticosteroids Market
Revenue (US$ Mn) and Forecasts, By Route of administration
16.7.6.3.1. Oral
16.7.6.3.2. Nasal
16.7.6.3.3. Intravenous
16.7.6.3.4. Rectal
16.7.6.3.5. Others
16.7.6.4. Rest of Middle East & Africa Corticosteroids Market
Revenue (US$ Mn) and Forecasts, By Forms
16.7.6.4.1. Tablets
16.7.6.4.2. Injectable Solutions
16.7.6.4.3. Gel/ Creams
16.7.6.4.4. Sprays
16.7.6.4.5. Others
16.7.6.5. Rest of Middle East & Africa Corticosteroids Market
Revenue (US$ Mn) and Forecasts, By End User
16.7.6.5.1. Hospitals
16.7.6.5.2. Specialty clinics
16.7.6.5.3. Pharmacies
16.7.6.5.3.1. Online
16.7.6.5.3.2. Retail
16.7.6.5.4. Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Drug Class
16.8.3. By Indication
16.8.4. By Route of administration
16.8.5. By Forms
16.8.6. By End User
17. Latin America Corticosteroids Market Analysis and Forecasts, 2022
- 2030
17.1. Overview
17.1.1. Latin America Corticosteroids Market Revenue (US$ Mn)
17.2. Latin America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
17.2.1. Glucocorticoid
17.2.2. Mineralocorticoids
17.3. Latin America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
17.3.1. Asthma
17.3.2. Inflammatory bowel diseases
17.3.3. Lupus
17.3.4. Rheumatoid arthritis
17.3.5. Chronic obstructive pulmonary disease (COPD)
17.3.6. Allergies
17.3.7. Multiple Sclerosis
17.3.8. Others
17.4. Latin America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
17.4.1. Oral
17.4.2. Nasal
17.4.3. Intravenous
17.4.4. Rectal
17.4.5. Others
17.5. Latin America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
17.5.1. Tablets
17.5.2. Injectable Solutions
17.5.3. Gel/ Creams
17.5.4. Sprays
17.5.5. Others
17.6. Latin America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
17.6.1. Hospitals
17.6.2. Specialty clinics
17.6.3. Pharmacies
17.6.3.1. Online
17.6.3.2. Retail
17.6.4. Others
17.7. Latin America Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Drug Class
17.7.1.1.1. Glucocorticoid
17.7.1.1.2. Mineralocorticoids
17.7.1.2. Brazil Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Indication
17.7.1.2.1. Asthma
17.7.1.2.2. Inflammatory bowel diseases
17.7.1.2.3. Lupus
17.7.1.2.4. Rheumatoid arthritis
17.7.1.2.5. Chronic obstructive pulmonary disease (COPD)
17.7.1.2.6. Allergies
17.7.1.2.7. Multiple Sclerosis
17.7.1.2.8. Others
17.7.1.3. Brazil Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Route of administration
17.7.1.3.1. Oral
17.7.1.3.2. Nasal
17.7.1.3.3. Intravenous
17.7.1.3.4. Rectal
17.7.1.3.5. Others
17.7.1.4. Brazil Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By Forms
17.7.1.4.1. Tablets
17.7.1.4.2. Injectable Solutions
17.7.1.4.3. Gel/ Creams
17.7.1.4.4. Sprays
17.7.1.4.5. Others
17.7.1.5. Brazil Corticosteroids Market Revenue (US$ Mn) and Forecasts,
By End User
17.7.1.5.1. Hospitals
17.7.1.5.2. Specialty clinics
17.7.1.5.3. Pharmacies
17.7.1.5.3.1. Online
17.7.1.5.3.2. Retail
17.7.1.5.4. Others
17.7.2. Argentina
17.7.2.1. Argentina Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Drug Class
17.7.2.1.1. Glucocorticoid
17.7.2.1.2. Mineralocorticoids
17.7.2.2. Argentina Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Indication
17.7.2.2.1. Asthma
17.7.2.2.2. Inflammatory bowel diseases
17.7.2.2.3. Lupus
17.7.2.2.4. Rheumatoid arthritis
17.7.2.2.5. Chronic obstructive pulmonary disease (COPD)
17.7.2.2.6. Allergies
17.7.2.2.7. Multiple Sclerosis
17.7.2.2.8. Others
17.7.2.3. Argentina Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Route of administration
17.7.2.3.1. Oral
17.7.2.3.2. Nasal
17.7.2.3.3. Intravenous
17.7.2.3.4. Rectal
17.7.2.3.5. Others
17.7.2.4. Argentina Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By Forms
17.7.2.4.1. Tablets
17.7.2.4.2. Injectable Solutions
17.7.2.4.3. Gel/ Creams
17.7.2.4.4. Sprays
17.7.2.4.5. Others
17.7.2.5. Argentina Corticosteroids Market Revenue (US$ Mn) and
Forecasts, By End User
17.7.2.5.1. Hospitals
17.7.2.5.2. Specialty clinics
17.7.2.5.3. Pharmacies
17.7.2.5.3.1. Online
17.7.2.5.3.2. Retail
17.7.2.5.4. Others
17.7.3. Rest of Latin America
17.7.3.1. Rest of Latin America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Drug Class
17.7.3.1.1. Glucocorticoid
17.7.3.1.2. Mineralocorticoids
17.7.3.2. Rest of Latin America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Indication
17.7.3.2.1. Asthma
17.7.3.2.2. Inflammatory bowel diseases
17.7.3.2.3. Lupus
17.7.3.2.4. Rheumatoid arthritis
17.7.3.2.5. Chronic obstructive pulmonary disease (COPD)
17.7.3.2.6. Allergies
17.7.3.2.7. Multiple Sclerosis
17.7.3.2.8. Others
17.7.3.3. Rest of Latin America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Route of administration
17.7.3.3.1. Oral
17.7.3.3.2. Nasal
17.7.3.3.3. Intravenous
17.7.3.3.4. Rectal
17.7.3.3.5. Others
17.7.3.4. Rest of Latin America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By Forms
17.7.3.4.1. Tablets
17.7.3.4.2. Injectable Solutions
17.7.3.4.3. Gel/ Creams
17.7.3.4.4. Sprays
17.7.3.4.5. Others
17.7.3.5. Rest of Latin America Corticosteroids Market Revenue (US$ Mn)
and Forecasts, By End User
17.7.3.5.1. Hospitals
17.7.3.5.2. Specialty clinics
17.7.3.5.3. Pharmacies
17.7.3.5.3.1. Online
17.7.3.5.3.2. Retail
17.7.3.5.4. Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Drug Class
17.8.3. By Indication
17.8.4. By Route of administration
17.8.5. By Forms
17.8.6. By End User
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2021
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Abbott
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. AstraZeneca
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. Cipla
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. GlaxoSmithKline plc
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Merck & Co., Inc
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Novartis
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. Pfizer
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. Sanofi
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Other Market Participants
20. Key Findings
Note: This ToC is tentative and can be changed
according to the research study conducted
during
the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.